NCT05117476CompletedPhase 1
A Phase 1 open-label, first-in-human, multi-center, dose escalation and dose expansion study of CLN-619 administered alone or in combination with pembrolizumab in patients with advanced solid tumors.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 19 Nov 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 240 (actual)
- First submitted
- 27 Feb 2024
- Start date
- 27 Jun 2022
- Lead sponsor
- Cullinan Mica Corp.
- NCT number
- NCT05117476
- EU CT number
- 2024-511744-27-00
- EudraCT number
- 2021-002473-26
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 240
- 8 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital HM Nou Delfos Coordinator of this site? Confirm its status | Barcelona | Spain | Completed |
| Complejo Hospitalario Universitario Insular Materno Infantil Coordinator of this site? Confirm its status | Las Palmas de Gran Canaria | Spain | Completed |
| Hospital Universitario Fundación Jiménez Díaz Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Clinica Universidad de Navarra Coordinator of this site? Confirm its status | Madrid | Spain | Completed |
| Clínica Universidad de navarra Coordinator of this site? Confirm its status | Pamplona | Spain | Completed |
| Biokinetica S.A. Coordinator of this site? Confirm its status | Jozefow | Poland | Completed |
| Med Polonia Sp z o.o. Coordinator of this site? Confirm its status | Poznan | Poland | Completed |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy Coordinator of this site? Confirm its status | Warsaw | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.